Product Development Leveraging the Functional Properties of Sugars
First written in FY2016. 12 of 19 entries say "Advanced", first in FY2017. Latest entry: FY2026.
31 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Full-scale production of Cup Oligo (galactooligosaccharides) had already begun at the Mihama Bioplant in Mihama Ward, Chiba, in April 2025, and production of CI (cyclodextran) also began at the plant in April 2026.」
Following Cup Oligo, CI also reached the stage of beginning production at the Mihama Bioplant in April 2026. - FY2026-H1AdvancedAnnual report
「The company proceeded with preparations to increase production of Cup Oligo and CI (cyclodextran) at the Mihama Bioplant.」
For Cup Oligo and CI, the initiative has progressed from the previous equipment investment and production expansion plans to the stage of preparing increased-production capacity at the Mihama Bioplant. The source does not state that operations have been completed or that full-scale production has begun. - FY2025AdvancedAnnual report
「For Cup Oligo (galactooligosaccharides), we invested in equipment at the Mihama Bioplant to further expand sales by increasing production capacity and promoting its functionality, and operations began in April 2025. In addition, we implemented sales promotion measures to raise awareness of CI (cyclodextran), which suppresses plaque formation and is manufactured and sold exclusively by the company worldwide, and invested in equipment for in-house production and increased output. Full-scale production is scheduled to begin during fiscal 2025.」
The equipment to expand Cup Oligo production capacity began operating in April 2025, while CI has also progressed to production expansion investment and plans to begin full-scale production during fiscal 2025. - FY2025-H1RestatedAnnual report
「In the Food Science business, shipments of Kib Oligo, our proprietary product, remained strong, supported by growing interest in its effects on the intestinal environment and sales activities aimed at expanding the number of adopting stores.」
The company has reconfirmed its ongoing sales activities to expand the number of stores adopting Kib Oligo and the continuation of strong shipments as initiatives for functional sweetener ingredients. - FY2024AdvancedAnnual report
「For functional sweetener ingredients that help improve the intestinal environment, such as Cup Oligo (galactooligosaccharides) and Kib Oligo (fructooligosaccharides), we will work to expand production capacity, raise awareness and increase sales. For cyclodextran, a proprietary group product expected to be effective in oral care, we will invest in equipment to increase production in response to future demand while also focusing on R&D to create further added value.」
The initiatives for functional sweetener ingredients have progressed to specific measures, including expanding production capacity for Cup Oligo and Kib Oligo, raising awareness and increasing sales, and investing in equipment and R&D to increase cyclodextran production. - FY2024-Q3RestatedAnnual report
「Amid these developments, shipments of the proprietary products Kibi sugar and Kibi Oligo remained strong.」
The Group has reaffirmed that shipments of Kibi sugar and Kibi Oligo, its proprietary products including functional sweeteners, remained strong. - FY2023AdvancedAnnual report
「Under the Food & Wellness pillar, we have designated functional ingredients as a priority area for the Group and established the Neo Functional Ingredients Department as a new organization directly under the President on 1 June 2023. In addition to seeking to expand sales of functional sweetener ingredients that help improve the intestinal environment, such as Cup Oligo (galactooligosaccharides) and Kibi Oligo (fructooligosaccharides), we will advance industry-academia research and development and further explore demand for functional ingredients such as kestose, a prebiotic ingredient, and the Group's proprietary cyclodextran, which is expected to have applications in oral care.」
The functional ingredients field has been designated a priority area, with concrete initiatives including the establishment of a new organization directly under the President and expanded sales, research and development for Cup Oligo, Kibi Oligo, kestose and cyclodextran. - FY2022RestatedAnnual report
「In addition to cyclodextran (CI), which has strong potential in oral care as one of our functional products, we will further advance initiatives involving Cup Oligo, which contributes to improving the intestinal environment.」
In addition to cyclodextran (CI), initiatives involving Cup Oligo continue as development targets for functional products. - FY2021AdvancedAnnual report
「As part of our comprehensive sweetener supplier strategy, we are promoting the development of new products using sugar and other sweeteners and research into new functions of galactooligosaccharides. At the Okinawa Laboratory, we are also conducting research and development on the functional carbohydrate cyclodextran (CI), which is expected to have applications in oral care and the solubilization of poorly soluble substances, and began manufacturing and sales in May 2021.」
Cyclodextran (CI), a functional carbohydrate, has progressed from research and development at the Okinawa Laboratory to the start of manufacturing and sales in May 2021. - FY2020RestatedAnnual report
「As part of our comprehensive sweetener supplier strategy, we are promoting the development of new products using sugar and other sweeteners and research into new functions of galactooligosaccharides, while also developing functional carbohydrates expected to offer anticaries properties and solubilize poorly soluble substances as part of our business-scope expansion.」
In addition to sweeteners and galactooligosaccharides, the development of functional carbohydrates continues as a core research and development area. - FY2018RestatedAnnual report
「For galactooligosaccharide products, including Oligo no Ōsama, launched in May 2017, we will promote consumer awareness by highlighting their functionality, including their benefits for improving the intestinal environment.」
The Group continues to promote the functionality of galactooligosaccharide products and build consumer awareness. - FY2018-Q3RestatedAnnual report
「Meanwhile, among other sweeteners, rollout to mass retailers is progressing for Oligo no Ōsama, a household syrup containing galactooligosaccharides that was launched in May.」
The progress of Oligo no Ōsama's rollout to mass retailers continues to be reported. - FY2018-Q1AdvancedAnnual report
「Among other sweeteners, rollout of the household syrup product containing galactooligosaccharides, Oligo no Ōsama, launched in May, to mass retailers is progressing.」
The galactooligosaccharide syrup Oligo no Ōsama was launched in May, and rollout to mass retailers is progressing. - FY2017AdvancedAnnual report
「In the field of functional polysaccharides such as oligosaccharides, as the importance of improving the intestinal environment to maintain and enhance health attracts growing attention, we entered the household products market by launching Oligo no Ōsama, a product containing galactooligosaccharides, in May.」
Oligo no Ōsama was launched in May in the functional polysaccharides field, marking entry into the household products market. - FY2016First statedAnnual report
「We are working to develop products that leverage the functionality of sugars.」
New product development leveraging the functionality of sugars is positioned as a measure to expand the business scope.